{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', '15. van Genderen FR, Westers P, Heijnen L, de Kleijn P, van den Berg HM, Helders PJ, et al.', \"Measuring patients' perceptions on their functional abilities: validation of the Haemophilia\", 'Activities List. Haemophilia. 2006 Jan; 12(1) 36-46.', '16. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and', 'preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011', 'Dec;20(10):1727-36', '17. Feldman BM, Funk SM, Bergstrom BM, Zourikian N, Hilliard P, van der Net J, et al.', 'Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis', 'Study Group: validity of the hemophilia joint health score. Arthritis Care Res (Hoboken). 2011', 'Feb;63(2):223-30.', 'Property of the Sanofi Group - strictly confidential', '75']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', '11.', 'APPENDICES', '11.1.', 'Pharmacokinetic Assessment Time Points', 'Table 7 provides a schedule for the collection of blood samples for PK analysis in all fitusiran', 'arm patients.', 'Table 7: Pharmacokinetic Time Points for All Fitusiran Arm Patients', 'Study Day', 'Protocol Time (hh:mm)', 'PK Blood', 'Predose', 'X', '(within 240 minutes before dosing)', 'Day 1', '04:00 (=30 min) a', 'X', 'Predose', 'Day 29 (7 days)', 'X', '(within 240 minutes before dosing)', 'Predose', 'Day 85 (=7 days)', 'X', '(within 240 minutes before dosing)', 'Predose', 'X', '(within 240 minutes before dosing) a', 'Day 197 (7 days)', '04:00 (=30 min) a', 'X', 'Predose', 'Day 225 (=7 days)', 'X', '(within 240 minutes before dosing)\u00b3 a', 'a Time point used in population PK analysis.', 'Property of the Sanofi Group - strictly confidential', '76']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Table 8 provides a schedule for the collection of blood samples for PK (fitusiran arm), AT, and', 'thrombin generation analysis in all East Asian patients, at East Asian sites.', 'Table 8: Pharmacokinetic (Fitusiran Arm), AT, and TG Time Points for East Asian Patients at', 'East Asian Sites', 'Protocol Time', 'Study Day', 'PK Blood', 'AT', 'TG', '(hh:mm)', 'Predose (within 240 minutes before', 'X', 'dosing)', '00:30 (=5 min)', 'X', '01:00 (=5 min)', 'X', 'Day 1', '02:00 (+15 min)', 'X', '04:00 (=30 min)', 'X', '06:00 (=30 min)', 'X', '08:00 (=30 min)', 'X', '12:00 (=30 min)', 'X', 'Day 2', '24:00 (=2 hours)', 'X', 'X', 'X', 'Day 8', '168 h', 'X', 'X', 'Day 29 (7', 'Predose (within 240 minutes before', 'X', 'days)', 'dosing)', 'Day 85 (=7', 'Predose (within 240 minutes before', 'X', 'days)', 'dosing)', 'Predose (within 240 minutes before', 'Day 197 (=7', 'X', 'dosing)\u00b3', 'days)', '04:00 (=30 min)', 'X', 'Day 225 (=7', 'Predose (within 240 minutes before', 'X', 'days)', 'dosing)', 'Abbreviations: AT=antithrombin; hh=hours; mm=minutes; PK=pharmacokinetics; TG=thrombin generation', 'a Time point used in population PK analysis.', 'Table 9 provides a schedule for the collection of pooled urine samples for PK analysis in East', 'Asian patients in the fitusiran arm at East Asian sites. Volume must be recorded.', 'Table 9: Urine Pharmacokinetic Time Points for East Asian Patients in the Fitusiran Arm', 'at East Asian Sites', 'Protocol Time', 'Study Day', '(hh:mm), Pooled Urine', 'Postdose (0:00) to 06:00 (=30 min)', 'Day 1', '06:00 (=30 min) to 12:00 (=30 min)', 'Day 2', '12:00 (=30 min) to 24:00 (=2 hours)', 'Property of the Sanofi Group - strictly confidential', '77']\n\n###\n\n", "completion": "END"}